Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1677 1678
This examiner grants 26% of resolved cases
Omar Ramadan serves as an examiner in Art Unit 1677 within Tech Center 1600. The examiner has managed 64 resolved cases, providing a dataset for understanding prosecution tendencies. The allowance rate is 23.4 percent, suggesting a highly challenging examination process. This 23.4 percent rate indicates that practitioners should be prepared for a rigorous and potentially difficult prosecution cycle in Art Unit 1677.
The median time to allowance is 1387 days, representing a significant period for applicants seeking to secure patent rights. This 1387-day duration is a key factor for strategic planning and client communication. The data also highlights an interview lift of 56.5 percent. This substantial lift is a critical metric, as it suggests that interviews are highly effective at overcoming rejections. Given the low 23.4 percent base rate, the 56.5 percent increase in success probability associated with interviews makes direct communication a vital tactic. Practitioners should prioritize interviews to navigate the 1387-day median pendency and improve the likelihood of a favorable outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17487534 | IMMUNOCHROMATOGRAPHY | Final Rejection | FUJIFILM Corporation |
| 17045312 | DIAGNOSTICS OF MILD OR ADVANCED PERIODONTITIS | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 18579084 | COMPOSITIONS AND TREATMENTS FOR CORONAVIRUS INFECTIONS | Non-Final OA | Ohio State Innovation Foundation |
| 17634843 | METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF | Final Rejection | Washington University |
| 18528268 | METHODS TO CHARACTERIZING A FRAGMENT CRYSTALLIZABLE DOMAIN OF A BISPECIFIC ANTIBODY | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17150504 | METHODS OF IDENTIFYING AN INDIVIDUAL AS HAVING OR BEING AT RISK OF DEVELOPING AN AMYLOID-POSITIVE DEMENTIA BASED ON MARKER MOLECULES AND RELATED USES | Final Rejection | Roche Diagnostics Operations, Inc. |
| 18438973 | AFFINITY REAGENTS HAVING ARTIFICIAL POLYMER SCAFFOLDS | Non-Final OA | Nautilus Subsidiary, Inc. |
| 17825867 | SOLUTION PHASE SINGLE MOLECULE CAPTURE AND ASSOCIATED TECHNIQUES | Final Rejection | Nautilus Subsidiary, Inc. |
| 18579702 | BIOCOMPATIBLE SURFACE FOR QUANTUM SENSING AND METHODS THEREOF | Non-Final OA | The University of Chicago |
| 17199926 | Rapid And Ultrasensitive Analyte Detection For Screening In Community Settings | Final Rejection | The Trustees of the University of Pennsylvania |
| 17423939 | DETECTION OF CEREBROSPINAL FLUID | Non-Final OA | Gwangju Institute of Science and Technology |
| 18675163 | DIAGNOSTICHOME KIT TODETECTMIDKINE LEVELIN BLOOD | Non-Final OA | PES University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy